Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 May;14(5):1217-8.
doi: 10.1093/humrep/14.5.1217.

Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women

A Murray  1 , J Webb, F MacSwiney, E L Shipley, N E Morton, G S Conway
Affiliations
Clinical Trial

Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women

A Murray et al. Hum Reprod. 1999 May.

Abstract

It is now recognized that female carriers of fragile X premutations are at increased risk of premature ovarian failure. We have studied 51 premenopausal women from fragile X families, to determine whether premutation carriers have variations in the hormonal markers of menopause, compared to full mutations and controls. We found a significant increase in serum follicle stimulating hormone in premutation carriers, suggesting that as a group they will enter menopause before full mutation carriers and unaffected controls. These results have important implications for fertility in these women.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Follicle stimulating hormone (FSH) concentrations plotted against age.
See this image and copyright information in PMC

References

    1. Allingham Hawkins DJ, Babul-Hirji D, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure. The International Collaborative premature ovarian failure in fragile X study. Am. J. Med. Genet. 1999 in press. - PMC - PubMed
    1. Blom G. Statistical Elements and Transformed Beta Variables. Wiley; New York: 1958.
    1. Conway GS, Hettiarachchi S, Murray A, Jacobs PA. Fragile X premutations in familial premature ovarian failure. Lancet. 1995;346:309–310. - PubMed
    1. Conway GS, Payne NN, Webb J, et al. Fragile X premutation screening in women with premature ovarian failure. Hum. Reprod. 1998;13:1184–1187. - PubMed
    1. MacNaughton J, Banah M, McCloud P, et al. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin. Endocrinol. 1992;36:339–345. - PubMed

Publication types

Substances